I like your numbers but $100m revenue won't be achieved in 1-2 years IMO.
To reach that will take some time but if revenues increase substantially each quarter, the market will take notice and revalue this accordingly.
If they can get to $10-$20m revenue for 2017, they will be doing well IMO.
Take a look at Pharmaxis with its EMA approval for Bronchitol. Revenues aren't impressive.
Obv FDA approval will be huge if Clinuvel are successful in Europe.
I like your numbers but $100m revenue won't be achieved in 1-2...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.12 |
Change
0.250(1.80%) |
Mkt cap ! $706.8M | |||
| Open | High | Low | Value | Volume |
| $13.90 | $14.17 | $13.90 | $675.2K | 48.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 293 | $14.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.12 | 261 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |